Abstract
Background: Recently a hot debate was raised to answer if intensive glycemic control aimed to reduce HbA1c to less than 6.5% is better than conventional therapy in terms of future outcomes. A lot of studies were conducted to explore that but few mega trials were conducted.
Objective: To evaluate the effect and safety of both intensive and conventional insulin therapy in patients with type 2 diabetes.
Methodology: Traditional systematic review was conducted; criteria for studies selection were formatted. Studies selected were criticized.
Results: Three mega trials (3) randomized 23182 participants with type 2 diabetes (11591 to intensive glycemic control and 11591 to conventional glycemic control) were included. Only diabetic nephropathy was noted to be delayed in onset or progression by intensive insulin therapy.
Conclusion: There are no benefits from intensive glycemic therapy (target HbA1c < 6.4%) vs conventional glycemic therapy (target HbA1c > 6.4%) except for decreasing the rate of new onset or progression of nephropathy.